Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Allakos ( (ALLK) ) has shared an update.
On April 1, 2025, Allakos Inc. entered into a Merger Agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Allakos for $0.33 per share in cash. The transaction, unanimously approved by Allakos’ Board of Directors, involves a tender offer for all outstanding shares and is expected to close by May 2025, subject to customary conditions. This merger positions Allakos as a wholly owned subsidiary of Concentra, potentially impacting stakeholders by consolidating operations and aligning with Concentra’s strategic objectives.
More about Allakos
Allakos Inc. is a biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells involved in allergy, inflammatory, and proliferative diseases.
YTD Price Performance: -82.50%
Average Trading Volume: 2,433,231
Technical Sentiment Signal: Buy
Current Market Cap: $20.53M
See more data about ALLK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue